Live feed
·
NEWSReleasevia Quantisnow
Protagenic Therapeutics Inc. logo

Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Positioning for Phase 2 in Stress & Mood Disorders

ByQuantisnow·Wall Street's wire, on your screen.
PTIX· Protagenic Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PTIX (Protagenic Therapeutics Inc.) and more on Quantisnow.